Rinascera Therapeutics

Rinascera Therapeutics is a private clinical-stage biotechnology company focused on transformative therapies for rare genetic skin diseases. The company launched publicly on July 16, 2026 and is headquartered in Boston, Massachusetts. Its initial pipeline includes RIN-001, a novel topical kinase inhibitor for Gorlin syndrome and high-frequency sporadic basal cell carcinomas, and RIN-002, an intravenous recombinant human collagen VII replacement therapy for dystrophic epidermolysis bullosa. Rinascera states that both programs have generated clinical proof-of-concept evidence and are being advanced into later-stage development. The company was incubated by Olive Tree Capital and launched with financing led by Double Point Ventures, with participation from Olive Tree Capital, Civilization Ventures, and Toba Capital.